GenoFocus Inc (187420) - Total Assets
Based on the latest financial reports, GenoFocus Inc (187420) holds total assets worth ₩136.10 Billion KRW (≈ $92.23 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check GenoFocus Inc investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
GenoFocus Inc - Total Assets Trend (2014–2025)
This chart illustrates how GenoFocus Inc's total assets have evolved over time, based on quarterly financial data. Explore investment intensity of GenoFocus Inc to see how much of total assets are deployed in long-term investments.
GenoFocus Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
GenoFocus Inc's total assets of ₩136.10 Billion consist of 36.8% current assets and 63.2% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 24.7% |
| Accounts Receivable | ₩7.86 Billion | 5.8% |
| Inventory | ₩7.06 Billion | 5.2% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩10.39 Billion | 7.7% |
| Goodwill | ₩5.37 Billion | 4.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how GenoFocus Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is GenoFocus Inc worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GenoFocus Inc's current assets represent 36.8% of total assets in 2025, a decrease from 49.4% in 2014.
- Cash Position: Cash and equivalents constituted 24.7% of total assets in 2025, down from 31.2% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 7.7% of total assets.
GenoFocus Inc Competitors by Total Assets
Key competitors of GenoFocus Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Akzo Nobel NV
AS:AKZA
|
Netherlands | €13.95 Billion |
|
Air Products and Chemicals Inc
NYSE:APD
|
USA | $41.24 Billion |
|
AKZO NOBEL SPONS.ADRS 1/3
F:AKUP
|
Germany | €15.49 Billion |
|
SKC Co. Ltd
KO:011790
|
Korea | ₩6.77 Trillion |
|
Shandong Dongyue Organosilicon Mat
SHE:300821
|
China | CN¥6.27 Billion |
|
Ningbo Shanshan Co Ltd
SHG:600884
|
China | CN¥45.88 Billion |
|
Jiangsu Ruitai New Energy Materials Co. Ltd.
SHE:301238
|
China | CN¥9.46 Billion |
|
5N Plus Inc.
TO:VNP
|
Canada | CA$519.27 Million |
GenoFocus Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.82 | 0.95 | 1.08 |
| Quick Ratio | 0.71 | 0.88 | 0.97 |
| Cash Ratio | 0.00 | 0.47 | 0.46 |
| Working Capital | ₩-11.39 Billion | ₩-4.10 Billion | ₩3.13 Billion |
GenoFocus Inc - Advanced Valuation Insights
This section examines the relationship between GenoFocus Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.60 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -7.1% |
| Total Assets | ₩135.83 Billion |
| Market Capitalization | $44.03 Million USD |
Valuation Analysis
Below Book Valuation: The market values GenoFocus Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: GenoFocus Inc's assets decreased by 7.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for GenoFocus Inc (2014–2025)
The table below shows the annual total assets of GenoFocus Inc from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩135.83 Billion ≈ $92.05 Million |
-7.13% |
| 2024-12-31 | ₩146.26 Billion ≈ $99.12 Million |
+49.46% |
| 2023-12-31 | ₩97.86 Billion ≈ $66.32 Million |
-26.92% |
| 2022-12-31 | ₩133.91 Billion ≈ $90.75 Million |
+12.99% |
| 2021-12-31 | ₩118.52 Billion ≈ $80.32 Million |
+4.68% |
| 2020-12-31 | ₩113.23 Billion ≈ $76.73 Million |
+25.53% |
| 2019-12-31 | ₩90.20 Billion ≈ $61.13 Million |
+28.25% |
| 2018-12-31 | ₩70.33 Billion ≈ $47.66 Million |
+0.26% |
| 2017-12-31 | ₩70.15 Billion ≈ $47.54 Million |
+10.95% |
| 2016-12-31 | ₩63.23 Billion ≈ $42.85 Million |
+107.14% |
| 2015-12-31 | ₩30.52 Billion ≈ $20.69 Million |
+80.17% |
| 2014-12-31 | ₩16.94 Billion ≈ $11.48 Million |
-- |
About GenoFocus Inc
HLB Genex, Inc. engages in the research and development, production, import/export, and sale of enzymes and fermentation products in South Korea and internationally. Its industrial special enzyme products include lactase; catalase for use in semiconductor industry; and proteinase K for molecular diagnostics and genetic engineering experiments, as well as bio-health care ingredients comprise N-phy… Read more